News

In September, we added 74 citations in DIDB, including 33 in vitro (with 12 articles published in September 2023) and 41 in vivo articles (with 22 articles published in September 2023).

6 recently approved NDAs/BLAs were also added: avacincaptad pegol (IZERVAY), lotilaner (XDEMVY), nirmatrelvir and ritonavir (PAXLOVID),palovarotene (SOHONOS),  somatrogon (NGENLA), talquetamab (TALVEY).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In August, we added 117 citations in DIDB, including 63 in vitro (with 23 articles published in August 2023) and 54 in vivo articles (with 30 articles published in August 2023).

3 recently approved NDAs/BLAs were also added: glofitamab (COLUMVI), nirsevimab (BEYFORTUS), quizartinib (VANFLYTA)

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In July, we added 110 citations in DIDB, including 55 in vitro (with 21 articles published in July 2023) and 55 in vivo articles (with 33 articles published in July 2023).

4 recently approved NDAs/BLAs were also added: flotufolastat F-18 gallium (POSLUMA), ritlecitinib (LITFULO), rozanolixizumab (RYSTIGGO), sulbactam and durlobactam (XACDURO)

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in July 2023, and is available in the DIDB Resource Center.

In this update, 25 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates and could lead to strong drug interactions mediated by CYP1A2, CYP2D6, and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In June, we added 77 citations in DIDB, including 22 in vitro (with 15 articles published in June 2023) and 55 in vivo articles (with 45 articles published in June 2023).

3 recently approved NDAs/BLAs were also added: leniolisib (JOENJA), pegunigalsidase alfa (ELFABRIO), fezolinetant (VEOZAH).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

“We are thrilled to share an important development related to Drug Interaction Solutions (DIS) and the DIDB^® – The Drug Interaction Database, which you and your teams have relied on over the years. As of June 21, 2023, DIS and DIDB^® have been acquired by Certara – a global leader in biosimulation and technology-enabled services that accelerate drug development. 

This move represents a significant milestone in the growth and development of DIDB^® and further strengthens its position as an internationally recognized authoritative, unbiased, and transparent drug development tool. As a part of Certara’s data sciences portfolio, we know we have found the right home for DIDB^® to continue towards becoming a standard in supporting drug development, healthcare applications, and complex clinical decision algorithms.”

UW CoMotion

In May, we added 107 citations in DIDB, including 45 in vitro (with 14 articles published in May 2023) and 62 in vivo articles (with 39 articles published in May 2023).

2 recently approved NDAs/BLAs were also added: retifanlimab (DAYBUE), tofersen (QALSODY).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.